Colchicine: Difference between revisions

Line 12: Line 12:


==Pediatric Dosing==
==Pediatric Dosing==
*Familial Mediterranea Fever (FMF)
*Familial Mediterranean Fever (FMF):
**Children 4 to 6 years: 0.3 to 1.8 mg daily in 1-2 divided doses
**Children 6 to 12 years: 0.9 to 1.8 mg daily in 1-2 divided doses
**Adolescents >12 years: Adult dosing
*Gout prophylaxis/treatment: Adult dosing


==Special Populations==
==Special Populations==

Revision as of 13:02, 16 June 2016

Administration

  • Type: Antigout
  • Dosage Forms: capsules, tablets
  • Routes of Administration: Oral
  • Common Trade Names: Colcris; Mitigare (US), Jamp-Colchicine, PMS-Colchicine

Adult Dosing

Gout

    • Flare treatment: Initial: 1.2 mg and then 0.6 mg in an hour (maximum 1.8 mg within 1 hour). In patient receiving prophylaxis treatment wait for 12 h after flare dosing before resuming prophylaxis dose. Do not repeat treatment for at least 3 days (Canadian labelling recommendation)
    • Prophylaxis Treatment: 0.6 mg twice daily (maximum 1.2 mg/day) for 3 months (without tophi) to 6 months (≥1 tophi) after reaching target serum uric acid levels [1]
  • Familial Mediterranean Fever (FMF): 1.2 mg to 2.4 mg per day in 1-2 decided dose. Titrate (increase or decrease) 0.3 mg daily increment based on efficacy and adverse effects.

Pediatric Dosing

  • Familial Mediterranean Fever (FMF):
    • Children 4 to 6 years: 0.3 to 1.8 mg daily in 1-2 divided doses
    • Children 6 to 12 years: 0.9 to 1.8 mg daily in 1-2 divided doses
    • Adolescents >12 years: Adult dosing
  • Gout prophylaxis/treatment: Adult dosing

Special Populations

Renal Dosing

  • Adult:
  • Pediatric:

Hepatic Dosing

  • Adult:
  • Pediatric:

Contraindications

  • Allergy to class/drug

Adverse Reactions

Serious

Common

Pharmacology

  • Half-life:
  • Metabolism:
  • Excretion:

Mechanism of Action

Comments

See Also

References

  1. Khanna D. et al.2012 ACR Guidelines for Management of Gout Part I: Systemic Non-pharmacologic and Pharmacologic Therapeutic Approach to Hyperuricemia. Arthritis Care Res (Hoboken). 2012 Oct; 64(10): 1431–1446.